Sign in or Register   Sign in or Register
  |  

Mouse Anti-CDK12 Recombinant Antibody (1H4) (CBMAB-A1857-LY)

The product is antibody recognizes CRKRS. The antibody 1H4 immunoassay techniques such as: WB, ELISA.
See all CDK12 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
1H4
Antibody Isotype
IgG1, κ
Application
WB, ELISA

Basic Information

Immunogen
CRKRS (NP_057591, 1281 a.a. ~ 1380 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Specificity
Human
Antibody Isotype
IgG1, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
cyclin-dependent kinase 12
Entrez Gene ID
51755
UniProt ID
Q9NYV4
Alternative Names
CRK7; CRKR; KIAA0904
Function
Cyclin-dependent kinase that phosphorylates the C-terminal domain (CTD) of the large subunit of RNA polymerase II (POLR2A), thereby acting as a key regulator of transcription elongation. Regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability. Preferentially phosphorylates 'Ser-5' in CTD repeats that are already phosphorylated at 'Ser-7', but can also phosphorylate 'Ser-2'. Required for RNA splicing, possibly by phosphorylating SRSF1/SF2. Involved in regulation of MAP kinase activity, possibly leading to affect the response to estrogen inhibitors.
Biological Process
mRNA processing Source: UniProtKB-KW
Negative regulation of stem cell differentiation Source: Ensembl
Phosphorylation of RNA polymerase II C-terminal domain Source: UniProtKB
Positive regulation of transcription elongation from RNA polymerase II promoter Source: GO_Central
Protein autophosphorylation Source: HGNC-UCL
Protein phosphorylation Source: GO_Central
Regulation of MAP kinase activity Source: UniProtKB
Regulation of RNA splicing Source: Ensembl
RNA splicing Source: UniProtKB
Transcription elongation from RNA polymerase II promoter Source: GO_Central
Cellular Location
Nucleus; Nucleus speckle. Colocalized with nuclear speckles throughout interphase.
Involvement in disease
Chromosomal aberrations involving CDK12 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with ERBB2, leading to CDK12-ERBB2 fusion leading to trunctated CDK12 protein not in-frame with ERBB2.
PTM
Phosphorylation at Thr-893 increases kinase activity.

Liu, H., Liu, K., & Dong, Z. (2021). Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery. Cancer research, 81(1), 18-26.

Rescigno, P., Gurel, B., Pereira, R., Crespo, M., Rekowski, J., Rediti, M., ... & de Bono, J. S. (2021). Characterizing CDK12-mutated prostate cancers. Clinical Cancer Research, 27(2), 566-574.

Reimers, M. A., Yip, S. M., Zhang, L., Cieslik, M., Dhawan, M., Montgomery, B., ... & Chou, J. (2020). Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer. European urology, 77(3), 333-341.

Liu, Y., Hao, M., Leggett, A. L., Gao, Y., Ficarro, S. B., Che, J., ... & Gray, N. S. (2020). Discovery of MFH290: a potent and highly selective covalent inhibitor for cyclin-dependent kinase 12/13. Journal of Medicinal Chemistry, 63(13), 6708-6726.

Thanindratarn, P., Dean, D. C., Feng, W., Wei, R., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2020). Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value. European Spine Journal, 29(12), 3214-3228.

Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020). CDK12: A potent target and biomarker for human cancer therapy. Cells, 9(6), 1483.

Emadi, F., Teo, T., Rahaman, M. H., & Wang, S. (2020). CDK12: a potential therapeutic target in cancer. Drug Discovery Today.

Antonarakis, E. S. (2018). Cyclin-dependent kinase 12, immunity, and prostate cancer. New England Journal of Medicine, 379(11), 1087-1089.

Lui, G. Y., Grandori, C., & Kemp, C. J. (2018). CDK12: an emerging therapeutic target for cancer. Journal of clinical pathology, 71(11), 957-962.

Johannes, J. W., Denz, C. R., Su, N., Wu, A., Impastato, A. C., Mlynarski, S., ... & Guichard, S. (2018). Structure‐Based Design of Selective Noncovalent CDK12 Inhibitors. ChemMedChem, 13(3), 231-235.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CDK12 Recombinant Antibody (1H4)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare